Photo of Kapil S. Meleveedu, M.D.

Kapil S. Meleveedu, M.D.

Assistant Professor of Medicine
Director, Blood and Marrow Transplantation
NPI Number:
1922353325
Academic Office Location:
Neag Comprehensive Cancer Center
UConn Health
263 Farmington Avenue
Farmington, CT 06030
Phone: 860-679-8992
860-679-2100
Website(s):

Carole and Ray Neag Comprehensive Cancer Center

Education
DegreeInstitutionMajor
M.B.B.S.Calicut Medical CollegeMedicine and Surgery

Post-Graduate Training
TrainingInstitutionSpecialty
InternshipYale New Haven Health/Bridgeport HospitalInternal Medicine
ResidencyYale New Haven Health/Bridgeport HospitalInternal Medicine
FellowshipUConn School of MedicineHematology/Oncology
FellowshipMayo ClinicBlood and Marrow Transplant
  • Autologous and allogeneic blood and marrow transplant and other cellular therapies including chimeric antigen receptor therapy (CART)
  • Hematological malignancies including acute leukemias such as acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and other myeloid disorders like myeloproliferative neoplasm (MPN) and myelofibrosis (MF)
  • Bone marrow failure conditions like severe aplastic anemia (SAA), myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH)
  • Aggressive lymphomas, plasma cell disorders
Name & DescriptionCategoryRoleTypeScopeStart YearEnd Year
American Society of Hematology (ASH)Professional/Scientific OrganizationMemberExternalNational
American Society of Clinical Oncology (ASCO)Professional/Scientific OrganizationMemberExternalNational
American Society of Transplantation and Cellular therapy (ASTCT)Professional/Scientific OrganizationMemberExternalNational

Journal Articles

Book Chapters

  • Acute lymphoblastic leukemia (ALL)
    Meleveedu, Kapil Ferri’s Clinical Advisor
  • Acute myeloid leukemia (AML)
    Meleveedu, Kapil Ferri’s Clinical Advisor
  • Myelodysplastic syndrome (MDS)
    Meleveedu, Kapil Ferri’s Clinical Advisor

Abstracts

  • Delaying Filgrastim Administration after Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Medawar G., Perez Rodriguez A., Cerio C., Todds R., Meleveedu K*. IJCCD 2022 Jun;2(Supplement 1):
  • De-Escalation of PTCy Dosing in Matched Allogenic Transplants: A Single Institution Retrospective Study
    Ackula, H., Medawar, M., Cerio, C., Roberts, TF., Meleveedu, K*. Blood 2021 Nov;138(Supplement 1):4872
  • The Cost Effectiveness of Delaying Filgrastim Administration after Autologous Stem Cell Transplant in Patients with Multiple Myeloma – a Single Institution Experience
    Medawar, G., Rodriguez, AP., Cerio, C., Roberts, TF., Meleveedu, K*. Blood 2021 Nov;138(Supplement 1):4959

Case Reports

Reviews

Title or AbstractTypeSponsor/EventDate/YearLocation
Cellular therapiesTalkUConn Health Cancer Center Event2023UConn Health
Overview of blood and marrow transplant and other cellular therapiesTalkInternal medicine grand rounds lecture2023UCONN Health
Blood and marrow transplant complications and role of ICU/critical careTalkPCCM grand rounds2023UCONN Health
Root cause analysis for all patients with delayed engraftment or graft failure at RWMCTalkBMT Quality meeting2022Roger Williams Medical Center. Providence, RI
The Cost Effectiveness of Delaying Filgrastim Administration after Autologous Stem Cell Transplant in Patients with Multiple Myeloma – a Single Institution ExperienceTalkBMT Quality meeting2021Roger Williams Medical Center. Providence, RI
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaTalkImmuno-Oncology JC series2020Roger Williams Medical Center. Providence, RI
HLH with primary bone marrow lymphoma – an unusual presentationPosterACP Annual Meeting, CT chapter2014Southington, CT
Delayed occurrence of Horner’s syndrome after chest tube removalPosterACP Annual Meeting, CT chapter2014Southington, CT
Atypical hemolytic uremic syndrome – a rapidly emerging entityPosterACP Annual Meeting, CT chapter2013Southington, CT